ClinicalTrials.gg
CompletedNCT00836888Updated Oct 8, 2020Results posted

ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan

A Phase 1 interventional study of ONO-4538 in Malignant Solid Tumor, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-10-08.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect and efficacy of ONO-4538.

02

Conditions studied

  • Malignant Solid Tumor

Keywords

  • ONO-4538
  • MDX-1106
  • solid tumors
03

In context

Lead sponsor

Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of solid tumor with at least one of ≥ 10mm.
  • Tumor must be advanced or recurrent which is to standard therapies or for which no alternative, appropriate therapy exists.
  • Performance Status of 0-1
  • ≥ 3 months
  • Other inclusion criteria as specified in the study protocol

Exclusion criteria

Exclusion Criteria:

  • History of severe reactions to other antibodies.
  • Residual adverse reactions or effect of prior therapy, which deemed to affect the safety evaluation of the study drug by the investigator or subinvestigator.
  • Two or more synchronous tumors, except for adequately treated basal cell cancer or cancer in situ, or superficial bladder cancer, or any other cancers from which the patient has been disease-free for at least 5 years.
  • Patients with any active disease or a documented history of chronic or recurrent autoimmune disease, or current medical condition that requires systemic doses of or other immunosuppressive medications.
  • Other exclusion criteria as specified in the study protocol
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Cohort

    Biological: ONO-4538

Interventions

  • BiologicalONO-4538

    1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts

06

What researchers measure

Primary outcomes

  1. Cmax at Single Dose

    Time frame: day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation

  2. AUClast at Single Dose

    Time frame: day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation

  3. T1/2 at Single Dose

    Time frame: day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation

  4. Ceoi at Multiple Doses

    Ceoi:Serum concentrations immediately after the end of continuous administration

    Time frame: day 15

Secondary outcomes

  1. Best Overall Response

    Response Evaluation Criteria In Solid Tumors Criteria (ver 1.0) was used for this Outcome Measure. Please see the reference for the detailed description. Therasse, Arbuck et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.

    Time frame: up to study completion, every 4 weeks in principle

07

Results

Posted Oct 8, 2020

Participant flow

Participant flow — Overall Study
MilestoneONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg Cohorts
Started3563
Completed0200
Not completed3363

Outcome measures

PrimaryCmax at Single Dose
Time frame:
day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation
Reported as:
Mean · μg/mL
Cmax at Single Dose
μg/mLONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg Cohorts
Cmax at Single Dose24.4 ± 4.568.8 ± 10.9192 ± 36214 ± 68
PrimaryAUClast at Single Dose
Time frame:
day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation
Reported as:
Mean · μg·h/mL
AUClast at Single Dose
μg·h/mLONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg Cohorts
AUClast at Single Dose4950 ± 58012300 ± 450043900 ± 720067400 ± 15500
PrimaryT1/2 at Single Dose
Time frame:
day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation
Reported as:
Mean · day
T1/2 at Single Dose
dayONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg Cohorts
T1/2 at Single Dose15 ± 013 ± 721 ± 1117 ± 9
PrimaryCeoi at Multiple Doses

Ceoi:Serum concentrations immediately after the end of continuous administration

Time frame:
day 15
Reported as:
Mean · μg/mL
Ceoi at Multiple Doses
μg/mLONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg Cohorts
Ceoi at Multiple Doses29.3 ± 6.0101 ± 12270 ± 42286 ± 112
SecondaryBest Overall Response

Response Evaluation Criteria In Solid Tumors Criteria (ver 1.0) was used for this Outcome Measure. Please see the reference for the detailed description. Therasse, Arbuck et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.

Time frame:
up to study completion, every 4 weeks in principle
Reported as:
Count of participants · Participants
Best Overall Response
ParticipantsONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg Cohorts
CR0100
PR1010
SD0120
PD2333
Unknown0000

Adverse events

Collected over All subjects treated with the study drug were followed up for at least 28 days after the last dose.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ONO-4538 1mg/kg Cohorts0/3 (0%)1/3 (33.3%)3/3 (100%)
ONO-4538 3mg/kg Cohorts0/5 (0%)1/5 (20%)5/5 (100%)
ONO-4538 10mg/kg Cohorts0/6 (0%)2/6 (33.3%)6/6 (100%)
ONO-4538 20mg/kg Cohorts0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg Cohorts
pain in extremityMusculoskeletal and connective tissue disorders1/30/50/60/3
malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/50/60/3
dehydrationMetabolism and nutrition disorders0/30/51/60/3
alanine aminotransferase increasedInvestigations0/30/51/60/3
aspartate aminotransferase increasedInvestigations0/30/51/60/3
blood bilirubin increasedInvestigations0/30/51/60/3
Most frequent other events
Showing 10 of 104
Most frequent other events
EventONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg Cohorts
Lymphocyte count decreasedInvestigations1/32/55/62/3
NauseaGastrointestinal disorders0/31/51/62/3
PyrexiaGeneral disorders1/31/52/62/3
Blood albumin decreasedInvestigations1/33/52/62/3
Blood creatine phosphokinase increasedInvestigations2/30/52/60/3
C-reactive protein increasedInvestigations1/32/52/62/3
Eosinophil count increasedInvestigations2/33/52/61/3
Decreased appetiteMetabolism and nutrition disorders1/30/53/62/3
DizzinessNervous system disorders0/31/50/62/3
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders0/30/50/62/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg CohortsTotal
<=18 years00000
Between 18 and 65 years145111
>=65 years21126
Sex: Female, Male
Sex: Female, Male(Participants)ONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg CohortsTotal
Female15017
Male206210
Performance Status(ECOG)
Performance Status(ECOG)(Participants)ONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg CohortsTotal
011204
1244313
disease stage classification
disease stage classification(Participants)ONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg CohortsTotal
IV03014
IVb00202
Recurrent324211
Cancer treatment history (surgery)
Cancer treatment history (surgery)(Participants)ONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg CohortsTotal
None01225
Present344112
Cancer treatment history (radiotherapy)
Cancer treatment history (radiotherapy)(Participants)ONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg CohortsTotal
None334212
Present02215
Cancer treatment history (drug therapy)
Cancer treatment history (drug therapy)(Participants)ONO-4538 1mg/kg CohortsONO-4538 3mg/kg CohortsONO-4538 10mg/kg CohortsONO-4538 20mg/kg CohortsTotal
None00101
Present355316
08

Study locations

1 site
  • Kanto Region, Kanto, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009 and a primary completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2020, 10 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2009
First posted
Feb 4, 2009
Start
Jan 2009
Primary completionActual
Sep 2010
Results first posted
Oct 8, 2020
Last update
Oct 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00836888
Responsible party
Sponsor
First posted
Feb 4, 2009
Start date
Jan 2009
Primary completion
Sep 2010
Results posted
Oct 8, 2020
Last update
Oct 8, 2020

Study contacts

Ohyama Yukiya
study director · Ono Pharmaceutical Co. Ltd
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion